🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "major milestone" in the fight against drug-resistant strains of the infection, according to health experts.

A Worldwide Health Concern

Cases of gonorrhoea are escalating around the world, with estimates suggesting in excess of 82 million infections annually. Particularly high rates are seen in the African continent and nations within the WHO's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely advancement in the reality of growing infection rates, escalating drug resistance and the highly restricted therapeutic options presently on offer.”

Medical experts are deeply concerned about the rise in drug-resistant strains. The WHO has designated it as a "priority pathogen". A tracking program showed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Gain Clearance

One new antibiotic, also known as a brand name, was approved by the US Food and Drug Administration in recent days for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Experts anticipate that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, also received approval in concurrent days. This medication, which is employed against UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a unique collaborative effort for medication research. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization marks a huge turning point in the treatment of superbug gonorrhoea, which previously has been outpacing antibiotic development.”

Testing Data and Global Access

Based on findings published in a prominent scientific publication, zoliflodacin eradicated the vast majority of cases of the STI. This puts it on an equal footing with the current standard treatment, which involves two antibiotics. The research involved nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the ability to register and commercialise the drug in numerous regions with limited resources.

Medical professionals directly involved have shared hope. Access to a single-dose, oral treatment like this is seen as a "critical tool" for managing the epidemic. This is deemed vital to reduce the burden of the illness for people and to prevent the spread of highly drug-resistant gonorrhoea worldwide.